NervGen Pharma Corp V.NGEN

Alternate Symbol(s): NGENF

Healthcare

NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer’s disease (AD) and multiple sclerosis (MS). Its NVG-291 is a therapeutic peptide, which is a mimetic of the intracellular domain of protein tyrosine phosphatase, a cell surface receptor known to interact with chondroitin sulfate proteoglycans (CSPGs) and to be involved in the regulation of neuroplasticity and central nervous system repair. It has also initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury. The Company's wholly owned subsidiaries include NervGen US Inc. and NervGen Australia Pty Ltd.

TSXV:NGEN - Post by User

NervGen Pharma Corp

<< Previous

Bullboard Posts

Next >>

Post by LowMooron Jan 08, 2024 2:18pm

193 Views

Post# 35816089

Insider buy today, a small amount. But its a buy.

Filed 2024-01-08 13:59 Tx date 2024-01-08	$NGEN NervGen Pharma Corp.	McKerracher, Krista 4 - Director of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$3,977 +2,000 vol $1.99 each	2,000